SAN FRANCISCO–(BUSINESS WIRE)–Hagens Berman, a national shareholder rights law firm, is investigating whether Corcept Therapeutics Inc. (NASDAQ: CORT) misled investors about relacorilant’s efficacy and commercial prospects. Corcept is under renewed scrutiny after Reuters reported on Jan. 30, 2026, that the FDA had warned the company “on several occasions” not to submit its application for relacorilant, its proposed treatment for hypercortisolism.
The report sent Corcept shares down, wiping out approximately $3.2 billion in market capitalization since December 2025.
The firm urges investors who suffered significant losses to contact Hagens Berman to learn more about their legal rights.
Key information:
- Investors who suffered losses are encouraged to report them.
- Website: www.hbsslaw.com/investor-fraud/cort
- Email: [email protected]
- Phone: 844-916-0895
- Video: youtube.com/watch?v=vMk3jcOV3Ng
About the Corcept Therapeutics (CORT) Investigation
Corcept promoted relacorilant’s efficacy and commercial potential, repeatedly assuring investors that its new drug application was “progressing toward approval by the end of” 2025. Company management also stated it was “[more] confident than ever” that Corcept was on track to grow its hypercortisolism business from $3 billion to $5 billion in annual revenue within three to five years.
On Dec. 31, 2025, however, Corcept revealed that it had received a complete response letter (CRL) from the FDA stating the agency could not reach a favorable benefit-risk assessment for relacorilant without additional evidence of effectiveness.
Corcept CEO Joseph K. Belanoff, MD, shared “[w]e are surprised and disappointed by this outcome[.]”
On Jan. 30, 2026, Reuters reported that the FDA had issued a corrected CRL dated Jan. 28, 2026, which disclosed that the agency had warned Corcept “on several occasions” not to submit its relacorilant application—apparently contradicting the company’s prior public statements regarding its communications with regulators.
“We’ve expanded our investigation to include whether Corcept misled investors about its FDA communications, in addition to relacorilant’s efficacy and safety,” said Reed Kathrein, Hagens Berman partner leading the investigation. “We are also examining whether the company overstated its hypercortisolism business.”
If you suffered substantial losses, contact Hagens Berman at www.hbsslaw.com/investor-fraud/cort.
Hagens Berman is a global plaintiffs’ rights law firm specializing in complex litigation and corporate accountability. The firm represents investors, whistleblowers, workers, and others harmed by corporate wrongdoing. Hagens Berman has secured $2.9 billion in this area of law. More at hbsslaw.com and @ClassActionLaw.
Contacts
Reed Kathrein, 844-916-0895
